Alteration of renal respiratory Complex-III during experimental type-1 diabetes
- 5.6k Downloads
Diabetes has become the single most common cause for end-stage renal disease in the United States. It has been established that mitochondrial damage occurs during diabetes; however, little is known about what initiates mitochondrial injury and oxidant production during the early stages of diabetes. Inactivation of mitochondrial respiratory complexes or alteration of their critical subunits can lead to generation of mitochondrial oxidants, mitochondrial damage, and organ injury. Thus, one goal of this study was to determine the status of mitochondrial respiratory complexes in the rat kidney during the early stages of diabetes (5-weeks post streptozotocin injection).
Mitochondrial complex activity assays, blue native gel electrophoresis (BN-PAGE), Complex III immunoprecipitation, and an ATP assay were performed to examine the effects of diabetes on the status of respiratory complexes and energy levels in renal mitochondria. Creatinine clearance and urine albumin excretion were measured to assess the status of renal function in our model.
Interestingly, of all four respiratory complexes only cytochrome c reductase (Complex-III) activity was significantly decreased, whereas two Complex III subunits, Core 2 protein and Rieske protein, were up regulated in the diabetic renal mitochondria. The BN-PAGE data suggested that Complex III failed to assemble correctly, which could also explain the compensatory upregulation of specific Complex III subunits. In addition, the renal F0F1-ATPase activity and ATP levels were increased during diabetes.
In summary, these findings show for the first time that early (and selective) inactivation of Complex-III may contribute to the mitochondrial oxidant production which occurs in the early stages of diabetes.
KeywordsRespiratory Complex Mitochondrial Respiratory Complex Rieske Protein Methyl Glyoxal Renal Mitochondrion
Blue Native Polyacrylamide Gel Electrophoresis
Ubiquinol:Cytochrome c oxidoreductase or Cytochrome bc1 complex
End Stage Renal Disease
Renal dysfunction is a major complication that affects 20–40% of individuals with diabetes  and diabetic nephropathy is the most common cause of end stage renal disease (ESRD) in the United States . Currently, no treatment options are available to prevent the renal complications of diabetes except for therapies which may slow the progression through intensive control of blood glucose and blood pressure . Thus, it is important to identify new therapeutic targets that might lead to the prevention of diabetes-induced nephropathy.
Several reports indicate that hyperglycemia-induced generation of superoxide within the mitochondria plays a major role in the development of diabetic complications [4, 5, 6, 7]. Nevertheless, the role that hyperglycemia has on renal mitochondrial respiratory complex function has not been thoroughly investigated. A few studies have indicated that diabetes induces alterations in the activities of mitochondrial respiratory complexes and mitochondrial respiration in the kidney [8, 9]. Rosca et al. demonstrated that renal Complex-III was a target for glycation and inhibition during chronic diabetes (12 months) . A study by Katyare and Satav showed that respiration rates and ATPase activity were elevated in diabetic renal mitochondria. This study also demonstrated that renal mitochondria were tightly coupled during diabetes . In addition, Complex-III has also been shown to be inhibited during chronic diabetes in diabetic mouse retina . Among the four respiratory complexes I through IV that comprise the electron transport chain, Complex-I and III are thought to be the major sources for superoxide generation within the mitochondria . However, the effect that short-term hyperglycemia has on renal mitochondrial complexes has not been examined in detail, and may lead to a more precise understanding of the initiating events involved with mitochondrial oxidant production during diabetes.
In this study, we have examined the status of renal mitochondrial complexes during the early stages (5-weeks) of experimental Type-1 diabetes using the streptozotocin-induced diabetes rat model. Our findings provide evidence for the first time that short-term diabetes caused selective Complex-III inactivation (with no effect on Complex I, II, or IV). In addition, further studies indicated that two Complex III subunits were induced following diabetes. These results suggest that in the early stages of hyperglycemia Complex III has assembly defects which could cause oxidant generation, leading to impairment of mitochondrial and renal function during hyperglycemia.
Streptozotocin-induced diabetes model
Male Sprague Dawley rats weighing 200 ± 50 g obtained from Harlan Sprague Dawley Inc. were used for this study. All of the animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Arkansas for Medical Sciences to perform as described in the paper. Rats were randomly divided into two groups: control and diabetic. Diabetes was induced by injecting overnight fasted rats with streptozotocin (STZ; 65 mg/kg, i.p.) dissolved in 0.5 ml saline, while the control rats were injected with 0.5 ml saline. Fasting blood glucose levels were measured 48 hours post-STZ injection and rats with blood glucose levels greater than 250 mg/dl were classified as "diabetic". Diabetes-induced changes were studied at 5 weeks post-STZ injection (n = 6).
Metabolic studies, organ harvest and blood collection
Animals were kept in metabolic cages and acclimatized overnight prior to urine collection. Urine was collected from each rat for 24 hr, and their 24 hr food and water intake were also measured. Animals were sacrificed under isoflurane anesthesia and their kidneys harvested. Blood was collected via intracardiac puncture and serum samples were stored at -80°C until used for creatinine measurement.
Creatinine clearance & urine albumin measurement
Serum creatinine (sCr) and urine creatinine (uCr) levels were measured by a modified Jaffe's method (Pointe Scientific, Canton, MI, USA) in a Cobas Mira clinical analyzer (Roche Diagnostics, Indianapolis, IN, USA). Creatinine clearance (CrCl) was then calculated from the formula: CrCl (ml/min/kg) = (uCr × uVolume × Body weight)/(sCr × 1440 min × 1000). Urine albumin levels were determined by an immunoturbidometric assay (Pointe Scientific, Canton, MI, USA) in a Cobas Mira clinical analyzer and expressed as mg/day/kg.
Periodic acid-Schiff (PAS) staining was performed on formalin fixed, paraffin embedded kidney sections to assess tubular integrity and renal morphology as previously described [12, 13]. Tissue sections were scored on a 0 to 4 scale by two pathologists blinded to the treatment groups according to the extent of tubular dilation and glomerular changes as follows: 0 = absent; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe.
Measurement of respiratory complex activities
Renal mitochondria were isolated from whole kidneys by differential centrifugation in a sucrose-containing buffer as previously described [14, 15]. The activity of mitochondrial Complexes-I through IV as described by Birch-Machin et al.  with minor modifications as previously described .
F o F 1 -ATP-ase (Complex-V) activity was assayed by measuring the release of Pi from ATP by the method of Law et al.. Each sample was run in the presence and absence of oligomycin (10 μg/ml), and the FoF1-ATP-ase activity was expressed as the oligomycin-sensitive ATPase activity.
Blue Native Gel Electrophoresis (BN-PAGE)
Mitochondrial complexes were analyzed by performing BN-PAGE on the control and diabetic mitochondria as previously described . To confirm the identity of mitochondrial Complex-III following BN-PAGE, the native gel was directly transferred to a PVDF membrane after first dimension and probed for known Complex III subunits Core 2 and Rieske subunits as described below. In addition, immunoblot analysis for Rieske and Core 2 subunits was performed following two-dimensional BN-PAGE by performing BN-PAGE, excising the Complex III bands, followed by SDS-PAGE in the second dimension.
ATP levels were determined in the mitochondrial fractions of control and diabetic rat kidneys using a luciferase based bioluminescent assay kit (Sigma-Aldrich, St. Louis, MO, USA) in a TD 20/20 luminometer (Turner Designs, Sunnyvale, CA, USA).
Immunoprecipitation of Complex-III
Complex-III was immunoprecipitated from control and diabetic rat renal mitochondria (2.5 mg) as described by Shilling et al.  using Complex-III immunocapture beads (MS301) from Mitosciences, USA. After SDS-PAGE, the gels were stained with Coomassie blue staining solution (0.1% bromophenol blue R-250 in 40% methanol and 10% acetic acid) for 30 minutes and then destained overnight in 7.5% acetic acid/5% methanol solution.
For immunoblotting, the gel was transferred to a PVDF membrane, and probed for Core 2 protein or the Rieske subunit using mouse monoclonal antibodies – MS304 or MS305 (Mitosciences) at 1:1,000 dilution overnight at 4°C. Blots were then probed with peroxidase labeled goat anti-mouse secondary antibody, and developed using an enhanced chemiluminescent substrate system.
Data analysis was performed using Origin 6.0. All values were expressed as mean ± SEM. Independent t-test (two-tailed) was used to compare the mean values between control and diabetic groups. Differences were considered statistically significant if the p values were less than 0.05.
Diabetic Rat Model
Rats made diabetic with STZ had fasting blood glucose levels of ~350 mg/dl, 48 hours after injection. Consistent with numerous reports, our diabetic rats (5-weeks post-STZ) showed a significant elevation in fasting blood glucose, 480.0 ± 69.3 mg/dl Vs 66.3 ± 3.8 mg/dl in an age-matched control group.
Metabolic effects of STZ-induced diabetes in rats.
Fasting blood glucose (mg/dl)
66.3 ± 3.8
480.0 ± 69.3*
Body weight (BW) (g)
371 ± 9.5
260.6 ± 17.6*
Food Intake (g/100 g BW)
5.7 ± 0.3
14.3 ± 0.4*
Water Intake (ml/100 g BW)
9.4 ± 1.7
73.2 ± 3.1*
Urine Output (ml/100 g BW)
3.4 ± 0.3
52.1 ± 2.9*
Diabetes induces hyperfiltration, albuminuria, and renal damage
Periodic Acid-Schiff (PAS) staining (which stains carbohydrates in brush borders, tubules, and glomerular basement membrane) was used to assess renal damage in the diabetic rat kidneys. Histological scoring of PAS stained kidney sections by two pathologists revealed that diabetes caused a moderate renal damage (a score of 0.17 in control Vs 2.0 in diabetic group) (Figure 1C).
Hyperglycemia induces specific alterations to renal mitochondrial respiratory complexes
To examine whether early diabetes had a significant impact on the renal mitochondrial respiratory chain, we used a relatively novel technique called Blue Native-Polyacrylamide Gel Electrophoresis (BN-PAGE). BN-PAGE directly detects the membrane bound mitochondrial respiratory complexes and, thus, can pinpoint which of the five respiratory complexes (I-V) show the most intense change in levels and assembly during diabetes .
Thus, Western blot analysis was performed for Rieske or Core 2 protein following Complex III immunoprecipitation. Diabetes appeared to increase Complex III associated Rieske and Core 2 proteins when compared to control kidneys (Figure 3B and 3C). The increased expression of specific Complex III subunits was further confirmed by Western blot analysis using renal mitochondria (without immunoprecipitation) which also showed an upregulation of the Complex-III subunits, Rieske (133.33 ± 3.1%) and Core 2 protein (136.69 ± 1.44%) during diabetes (Figure 3D and 3E) as compared to control. GAPDH was used as the loading control.
These results indicate that renal Complex-III appears to be an early and specific mitochondrial target during experimental type-1 diabetes. Complex-III is centrally located in the electron transfer process and has been implicated as one of the major sites for superoxide generation in the mitochondria during diabetes [8, 10]. Partial inhibition of Complex-III during conditions of increased respiration  would decrease the transfer of electrons from ubiquinol to Complex-III, and increase the half-life of ubisemiquinone, which leads to generation of superoxide [8, 10].
Intriguingly, our results indicated an upregulation of renal Complex-III subunits, Core 2 and Rieske protein during diabetes. However, using BN-PAGE it was shown that Complex III was not correctly assembled (decreased levels on BN-PAGE) which also correlated with a decrease in Complex-III activity. Thus, the paradoxical increase in expression of individual subunits, Core 2 and Rieske proteins could be a compensatory response to restore the activity of Complex-III during diabetes.
Rieske subunit is a nuclear encoded protein that is imported into the mitochondrial matrix where it undergoes a two-step cleavage of its pre-sequence and is translocated into the inner mitochondrial membrane. It has an iron-sulfur [2Fe-2S] redox center that centrally participates in the Q cycle by transferring an electron from ubiquinol to cytochrome c1, which then donates it to cytochrome c. Core 2 subunit, which is also a nuclear encoded protein is a homolog of mitochondrial processing protease-alpha subunit and is thought to be important for mitochondrial protein import, processing and integrity of Complex-III . Although, Core 2 subunit is not primarily involved in electron transfer, genetic deletion of Core 2 has been shown to affect the assembly of Complex-III . Thus, an increase in the Rieske as well as the Core 2 subunits suggests a possible assembly defect in Complex-III.
To our knowledge, this is the first report demonstrating that renal Complex-III and its subunits are altered in the early stages of diabetes. A study by Rosca et al. showed previously that Complex-III was a target for glycation by methyl glyoxal and inactivated during chronic diabetes (12 months) , while no significant changes were reported at 2 months of diabetes. Although, the reason for this discrepancy remains unknown; one difference could be the fraction of the kidney analyzed in the two studies. Our study utilized whole rat kidneys, whereas the study by Rosca et al. used the cortical fractions of kidneys. Although the renal cortex has been primarily considered to be the energetically active segment of the nephron, several studies suggest that the medullary thick ascending limb (mTAL) is an active site for reabsorption in kidney and thus might play a major role in mitochondrial superoxide production. In addition, increased oxidant production has been observed in both the cortical and medullar regions of the kidney. Thus, we felt it was important to include both cortex and medulla (whole kidney) for mitochondrial isolation and study the net effect of diabetes on the renal mitochondria.
Despite the findings by Katyare and Satav  who showed increased cytochrome aa3 contents in renal mitochondria during diabetes, we did not detect any significant changes in Complex IV activity in our rat model of diabetes. It is also important to note that the authors could not correlate the changes in cytochrome content with the altered respiration rates observed during diabetes. In addition, these authors did not measure Complex IV activity and we did not measure cytochrome aa3 contents so a direct comparison of these studies is difficult to assess. Again, one important difference between the two studies is the source of renal mitochondria used: we used whole kidney mitochondria, while Katyare and Satav used cortical mitochondria as discussed above.
Our results also showed that F0F1-ATPase activity and renal ATP levels were significantly increased in the diabetic renal mitochondria compared to controls. Interestingly, the study by Katyare and Satav  also demonstrated that respiration and ATPase activity were increased in diabetic renal mitochondria. Thus, it is possible that the increased respiration leads to increased proton motive force (hyperpolarization) and increased ATP levels which serve to fulfill the increased energy demands of the kidney during diabetes. Concomitantly, the increased respiration would likely result in more superoxide (oxidant) generation which could lead to alterations in Complex III. In fact, we have observed that renal proximal tubule cells exposed to hyperglycemia (25 mM; 48 hr) results in mitochondrial hyperpolarization, Complex-III inhibition, and oxidant production (manuscript under review).
In conclusion, we have demonstrated that early stages of diabetes induced alterations in Complex-III, increased ATP synthase activity, and renal dysfunction. These diabetes-induced alterations in activities of mitochondrial complexes and energy status could contribute to the underlying role of oxidative stress in the pathogenesis of diabetic nephropathy. Our future in vitro studies will explore the mechanistic pathways by which hyperglycemia induces mitochondrial complex dysfunction and oxidant production. Finally, strategies to limit the extent of renal mitochondrial damage during hyperglycemia (by therapeutic agents that will specifically modulate mitochondrial function) might prevent or inhibit the development of nephropathy in the diabetic population.
We thank Drs. John P. Crow and Philip R. Mayeux for their valuable comments and discussion.
This research study was funded by a Pilot grant from University of Arkansas for Medical Sciences, Little Rock, AR.
- 2.U.S. Renal Data System: USRDS 2008 Annual Report, in Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute for Diabetes and Digestive and Kidney Diseases. 2008Google Scholar
- 5.Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. PNAS. 2000, 97: 12222-12226.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Schilling B, Murray J, Yoo CB, Row RH, Cusack MP, Capaldi RA, Gibson BW: Proteomic analysis of succinate dehydrogenase and ubiquinol-cytochrome c reductase (Complex II and III) isolated by immunoprecipitation from bovine and mouse heart mitochondria. Biochim Biophys Acta. 2006, 1762: 213-222.CrossRefPubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/9/2/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.